Celestial Therapeutics
Celestial Therapeutics is a pioneering biotech company focused on developing innovative therapies, including antivirals, anti-inflammatories, mRNA vaccines, and therapeutics to treat, prevent, and cure infectious diseases, rare diseases, and cancers. With a mission to address unmet medical needs and reduce healthcare costs, the company leverages groundbreaking science and proprietary platform technologies to bring novel solutions to global health challenges.
Industries
Nr. of Employees
small (1-50)
Celestial Therapeutics
San Diego, California, United States
Products
Pulmonary surfactant lipid-based inhalation therapeutic candidate (lead)
A pulmonary surfactant–derived lipid therapeutic being developed as a dual-modal antiviral and anti-inflammatory inhalation product for respiratory infections, with formulation work toward dry powder ambient-stable delivery.
Next-generation self-adjuvanting mRNA vaccine platform and prototype candidates
A licensed mRNA platform that encodes antigen and built-in immunostimulatory RNA to enhance immunogenicity while enabling tunable adjuvant activity; prototype work includes a candidate against Chikungunya for preclinical evaluation.
Pulmonary surfactant lipid-based inhalation therapeutic candidate (lead)
A pulmonary surfactant–derived lipid therapeutic being developed as a dual-modal antiviral and anti-inflammatory inhalation product for respiratory infections, with formulation work toward dry powder ambient-stable delivery.
Next-generation self-adjuvanting mRNA vaccine platform and prototype candidates
A licensed mRNA platform that encodes antigen and built-in immunostimulatory RNA to enhance immunogenicity while enabling tunable adjuvant activity; prototype work includes a candidate against Chikungunya for preclinical evaluation.
Services
Collaborative preclinical development partnerships, academic licensing and joint research initiatives to advance vaccine and therapeutic prototypes.
Collaborative preclinical development partnerships, academic licensing and joint research initiatives to advance vaccine and therapeutic prototypes.
Expertise Areas
- mRNA vaccine development
- Lipid-based inhalation therapeutics
- Preclinical safety and immunogenicity testing
- Formulation and delivery for respiratory indications
Key Technologies
- Self-adjuvanting mRNA constructs
- Lipid nanoparticle formulation
- Pulmonary surfactant-derived lipids
- Dry powder inhalation formulation
News & Updates
Celestial Therapeutics Inc. has been accepted into Johnson & Johnson Innovation – JLABS as a resident company at its flagship site in San Diego, California.
Dr. George Siber, a vaccine expert with over 40 years of experience, has joined Celestial’s Board of Directors.
Celestial has been selected to join NYU Stern’s Endless Frontier Labs program to accelerate its research and development.
Celestial received a $2,024,890 SBIR Fast Track grant from NIH to develop a dry powder inhalation therapeutic for RSV.
Dr. Michael Houghton, Nobel laureate for hepatitis C research, has joined Celestial’s Scientific Advisory Board.
Celestial Therapeutics Inc. has been accepted into Johnson & Johnson Innovation – JLABS as a resident company at its flagship site in San Diego, California.
Dr. George Siber, a vaccine expert with over 40 years of experience, has joined Celestial’s Board of Directors.
Celestial has been selected to join NYU Stern’s Endless Frontier Labs program to accelerate its research and development.
Celestial received a $2,024,890 SBIR Fast Track grant from NIH to develop a dry powder inhalation therapeutic for RSV.
Dr. Michael Houghton, Nobel laureate for hepatitis C research, has joined Celestial’s Scientific Advisory Board.